menu

Targeting IL-13 in Moderate to Severe Atopic Dermatitis: Forging a New Path to Improved Disease and Patient Outcomes

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Targeting IL-13 in Moderate to Severe Atopic Dermatitis: Forging a New Path to Improved Disease and Patient Outcomes

1.00 credits
60 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Atopic dermatitis (AD) significantly impacts physical, social, and psychological well-being. Recently, novel and more effective treatment options have been approved, including those targeting interleukin (IL)-13. Tune in to watch this webcast on incorporating these agents to optimize care for patients with moderate to severe AD with Terry Faleye, Dermatology Physician Assistant at DermSurgery Associates in Houston, Texas, and Dr. Jonathan Silverberg, Professor, Director of Clinical Research, and Director of Patch Testing at George Washington University School of Medicine and Health Sciences in Washington, DC.

  • Disclosure of Conflicts of Interest

    Partners for Advancing Clinical Education (PACE) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 
    The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity.

    Faculty disclosures: The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity.

    • Jonathan I. Silverberg, MD, PHD, MPH: consultant/advisor: AbbVie, Aobiome, Arcutis, Amgen, Arena, Asana, Aslan, BioMX, Biosion, Bodewell, Boehringer Ingelheim, Cara, Castle Biosciences, Celgene, Connect Biopharma, Dermavant, Dermira, Dermtech, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo, Lilly, Menlo, Novartis, Optum, Pfizer, RAPT, Regeneron, Sanofi, Shaperon, Union.
    • Terry Faleye, MPAS, PA-C: consultant/advisor/speaker: AbbVie, Bristol Myers Squibb, Eli Lilly, EPI Health, Leo Pharma, Novartis, Regeneron, Sun Pharma.
    • The planners and content peer reviewers from Partners for Advancing Clinical Education and Practicing Clinicians Exchange do not have any relevant financial relationships to disclose.
  • Disclosure Statement

    Partners for Advancing Clinical Education (PACE) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Target Audience

    This program is primarily intended for NPs and PAs who practice in dermatology.

  • Learning Objectives

    Upon completion of this activity, participants should be able to:

    • Recognize the burden of AD and its impact on patients
    • Detail the targeted mechanism of action of IL-13 therapy in moderate to severe AD and its potential impact on disease and patient outcomes
    • Incorporate patient-specific preferences and goals into treatment clinical decision-making discussions 
  • Accreditation and Credit Designation Statements

    Joint Accreditation Statement

     

     

    In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    ANCC Credit Designation
    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour, including 1.0 hour of pharmacology credit.

    AAPA Credit Designation

     

    Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until May 14, 2024. PAs should only claim credit commensurate with the extent of their participation.

     IPCE Credit Designation

     

    This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

     

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

  • Provider(s)/Educational Partner(s)


    Provided by Partners for Advancing Clinical Education (PACE).

  • Commercial Support

    This activity is supported by an educational grant from Lilly.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Atopic dermatitis (AD) significantly impacts physical, social, and psychological well-being. Recently, novel and more effective treatment options have been approved, including those targeting interleukin (IL)-13. Tune in to watch this webcast on incorporating these agents to optimize care for patients with moderate to severe AD with Terry Faleye, Dermatology Physician Assistant at DermSurgery Associates in Houston, Texas, and Dr. Jonathan Silverberg, Professor, Director of Clinical Research, and Director of Patch Testing at George Washington University School of Medicine and Health Sciences in Washington, DC.

  • Disclosure of Conflicts of Interest

    Partners for Advancing Clinical Education (PACE) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 
    The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity.

    Faculty disclosures: The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity.

    • Jonathan I. Silverberg, MD, PHD, MPH: consultant/advisor: AbbVie, Aobiome, Arcutis, Amgen, Arena, Asana, Aslan, BioMX, Biosion, Bodewell, Boehringer Ingelheim, Cara, Castle Biosciences, Celgene, Connect Biopharma, Dermavant, Dermira, Dermtech, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo, Lilly, Menlo, Novartis, Optum, Pfizer, RAPT, Regeneron, Sanofi, Shaperon, Union.
    • Terry Faleye, MPAS, PA-C: consultant/advisor/speaker: AbbVie, Bristol Myers Squibb, Eli Lilly, EPI Health, Leo Pharma, Novartis, Regeneron, Sun Pharma.
    • The planners and content peer reviewers from Partners for Advancing Clinical Education and Practicing Clinicians Exchange do not have any relevant financial relationships to disclose.
  • Disclosure Statement

    Partners for Advancing Clinical Education (PACE) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Target Audience

    This program is primarily intended for NPs and PAs who practice in dermatology.

  • Learning Objectives

    Upon completion of this activity, participants should be able to:

    • Recognize the burden of AD and its impact on patients
    • Detail the targeted mechanism of action of IL-13 therapy in moderate to severe AD and its potential impact on disease and patient outcomes
    • Incorporate patient-specific preferences and goals into treatment clinical decision-making discussions 
  • Accreditation and Credit Designation Statements

    Joint Accreditation Statement

     

     

    In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    ANCC Credit Designation
    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour, including 1.0 hour of pharmacology credit.

    AAPA Credit Designation

     

    Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until May 14, 2024. PAs should only claim credit commensurate with the extent of their participation.

     IPCE Credit Designation

     

    This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

     

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

  • Provider(s)/Educational Partner(s)


    Provided by Partners for Advancing Clinical Education (PACE).

  • Commercial Support

    This activity is supported by an educational grant from Lilly.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule27 Feb 2024